Tools to support a clinical aTTP diagnosis

Plasmic and French scores can be used to predict ADAMTS13 deficiency¹

Plasmic and French scores are based on laboratory parameters such as platelet count and creatinine level.²

Rapidly identifying thrombotic thrombocytopenic purpura (TTP) can save lives¹

TTP is a life-threatening thrombotic microangiopathy (TMA) that requires quick diagnosis and urgent treatment. ^1,2

TTP is a life-threatening thrombotic microangiopathy (TMA) that requires quick diagnosis and urgent treatment. ^1,2

TTP is a life-threatening thrombotic microangiopathy (TMA) that requires quick diagnosis and urgent treatment. ^1,2

MAT-AE-2200643-V1-Nov-22

Parameter		Score
Platelet count <30 × 10⁹/L		+1
Serum creatinine level <2.0 mg/dL		+1
Evidence of hemolysis*: Indirect bilirubin >2.0 mg/dL or Reticulocyte count >2.5% or Undetectable haptoglobin		+1
No active cancer in previous year*		+1
No history of solid organ or stem cell transplantation*		+1
INR <1.5*		+1
MCV <90 fL (<9.0 × 10^-14/L)^†		+1
Likelihood of severe ADAMTS13 deficiency^‡	Low risk	0 to 4: 0% to 4%
	Intermediate risk	5: 5% to 24%
	High risk	6 to 7: 62% to 82%

Validation of the Plasmic score¹
	Derivation validation cohort (n=200)	Internal validation cohort (n=150)	External validation cohort (n=146)
0-4	0/84 (0%)	0/89 (0%)	2/47 (4%)
5	2/44 (5%)	3/32 (9%)	6/25 (24%)
6-7	58/72 (81%)	18/29 (62%)	61/74 (82%)

Prediction of severe ADAMTS13 deficiency (activity <10%) based on score^‡	0: 2%
	1: 70%
	2: 94%